RETRACTED: The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice

RETRACTED ARTICLE   Introduction. CDK4/6 inhibitors in combination with endocrine therapy (ET) are the current standard of care for patients with HR+ HER2- advanced and metastatic breast cancer (eBC and mBC). Evidence of the clinical efficacy of CDK4/6 inhibitors has been obtained in several randomi...

Descripción completa

Detalles Bibliográficos

Autores principales:	I. E. Khatkov, I. I. Andreyashkina, I. D. Trotsenko, O. N. Matveeva, V. A. Reznikov
Formato:	Artigo
Lenguaje:	Russo
Publicado:	Publishing House OKI 2025-07-01
Colección:	Реальная клиническая практика: данные и доказательства
Materias:	ингибиторы cdk4/6 рибоциклиб палбоциклиб абемациклиб реальная клиническая практика местнораспространённый рак молочной железы метастатический рак молочной железы
Acceso en línea:	https://www.myrwd.ru/jour/article/view/105
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!